Atovaquone proguanil contraindications: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 11: | Line 11: | ||
===Severe Renal Impairment=== | ===Severe Renal Impairment=== | ||
MALARONE is contraindicated for prophylaxis of [[P. falciparum malaria]] in patients with severe renal impairment (creatinine clearance <30 mL/min) because of [[pancytopenia]] in patients with severe renal impairment treated with proguanil [see Use in Specific Populations | MALARONE is contraindicated for prophylaxis of [[P. falciparum malaria]] in patients with severe renal impairment (creatinine clearance <30 mL/min) because of [[pancytopenia]] in patients with severe renal impairment treated with proguanil [see Use in Specific Populations , and Clinical Pharmacology ].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MALARONE (ATOVAQUONE AND PROGUANIL HYDROCHLORIDE) TABLET, FILM COATED [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fc22e8d8-3bfb-4f70-a599-dd81262a4887 | publisher = | date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
Latest revision as of 05:38, 7 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Contraindications
Hypersensitivity
MALARONE is contraindicated in individuals with known hypersensitivity reactions (e.g., anaphylaxis, erythema multiforme or Stevens-Johnson syndrome, angioedema, vasculitis) to atovaquone or proguanil hydrochloride or any component of the formulation.
Severe Renal Impairment
MALARONE is contraindicated for prophylaxis of P. falciparum malaria in patients with severe renal impairment (creatinine clearance <30 mL/min) because of pancytopenia in patients with severe renal impairment treated with proguanil [see Use in Specific Populations , and Clinical Pharmacology ].[1]
References
Adapted from the FDA Package Insert.